HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MASS
908 Devices Inc.
MASS lost money over the past year, so it has no meaningful PE right now.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MASS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
MASS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MASS PE Valuation
MASS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MASS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
MASS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MASS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.53 |
| Q2 2026 | -$0.96 | -$0.40 |
| Q1 2026 | -$1.01 | -$0.45 |
| Q4 2025 | $0.54 | +$2.66 |
| Q3 2025 | -$0.13 | +$1.64 |
| Q2 2025 | -$0.56 | +$0.59 |
| Q1 2025 | -$0.56 | +$0.51 |
| Q4 2024 | -$2.12 | -$0.99 |
MASS is still losing money, but far less than before: $0.66 per share over the past year, against $2.12 at its worst in late 2024.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MASS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MASS on profitability, with a higher operating margin.
MASS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +35% |
| Q2 2026 | $16.1M | +23% |
| Q1 2026 | $13.4M | +14% |
| Q4 2025 | $17.4M | -7.7% |
| Q3 2025 | $14M | -17% |
| Q2 2025 | $13M | -7.2% |
| Q1 2025 | $11.8M | +18% |
| Q4 2024 | $18.8M | +31% |
MASS's revenue is growing: $19M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -29% | +88 points |
| Q2 2026 | -80% | +37 points |
| Q1 2026 | -96% | -2.7 points |
| Q4 2025 | 18% | +125 points |
| Q3 2025 | -117% | +64 points |
| Q2 2025 | -116% | -20 points |
| Q1 2025 | -94% | +33 points |
| Q4 2024 | -108% | -40 points |
MASS's operating margin was −29% last quarter, up 88 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MASS on cash flow, with more consistent year-over-year improvement.
MASS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$2M |
| Q2 2026 | $3M | +$8.9M |
| Q1 2026 | $1.2M | +$16.3M |
| Q4 2025 | $1.3M | +$3.8M |
| Q3 2025 | -$4.9M | +$879K |
| Q2 2025 | -$5.9M | +$6.5M |
| Q1 2025 | -$15.2M | -$4.9M |
| Q4 2024 | -$2.4M | -$170K |
MASS's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MASS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MASS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.9% | +3.3M shares |
| 1 year | +14% | +5M shares |
| 3 years | +27% | +8.7M shares |
| 5 years | +48% | +13.4M shares |
| Available history | +492% | +34.1M shares |
MASS has 41M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MASS Net Leverage
MASS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MASS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.5 | Neutral |
| Stochastic | 46.7 | Neutral |
MASS's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MASS PE vs Healthcare Sector
MASS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MASS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 14% below |
| 20 week MA | $10.0 | 2.2% below |
| 50 week MA | $8.06 | 21% above |
| 100 week MA | $6.71 | 46% above |
| 200 week MA | $6.59 | 49% above |
MASS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MASS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $67.9 | +39% |
| 2021 | $67.9 | $26.6 | -61% |
| 2022 | $26.6 | $7.31 | -73% |
| 2023 | $7.31 | $11.2 | +53% |
| 2024 | $11.2 | $2.26 | -80% |
| 2025 | $2.26 | $5.41 | +139% |
| 2026 YTD | $5.41 | $9.79 | +81% |
MASS has the edge over HIMS on returns for 2026, with the stronger performance.